Clínic Barcelona
Investigación

Preclinical results support a new combinatorial treatment for follicular Lymphoma to target the tumor cell and its immune microenvironment

Researchers from the “Microenvironment in Lymphoma Pathogenesis and Therapy” IDIBAPS research group have identified a fingerprint to predict the sensitivity to the PI3Kδ inhibitor idelalisib, and proposed a novel rational-based combined therapy in follicular lymphoma (FL), the most common type of indolent lymphoma. These results have been published in Blood Advances, the open access journal of the American Society of Hematology.

Lee más sobre: